Valuation : Alector, Inc.

Market Cap 239M 206M 195M 177M 331M 22.83B 333M 2.32B 890M 11.61B 897M 878M 36.7B P/E 2026 *
-2.49x
P/E 2027 * -3.07x
Enterprise Value 11.48M 9.89M 9.36M 8.49M 15.92M 1.1B 16M 111M 42.77M 558M 43.11M 42.16M 1.76B EV / Sales 2026 *
1.05x
EV / Sales 2027 * -2.21x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Alector, Inc.

1 week-13.01%
Current month-5.31%
1 month+2.39%
3 months+36.31%
6 months-7.76%
Current year+37.18%
1 week 2
Extreme 2
2.61
1 month 1.9
Extreme 1.9
2.76
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27.05
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Sell

Controller/Auditor

-3,625 0.0032%
3/9/26 Sell

Chief Financial Officer

-29,251 0.0262%
3/9/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.01%-25.44%-63.29% 239M
-2.11%-1.68%+44.52%+95.15% 68.24B
-0.23%-4.45%+30.39%+73.64% 62.23B
+1.67%+2.47%-11.23%+388.34% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
+0.34%-6.78%-7.27%-17.99% 24.22B
+0.43%-3.37%+14.85%-19.29% 19.36B
-3.03%-2.29%+185.12%+334.07% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-2.28%-4.90%+43.64%+155.21% 14.23B
Average -0.82%-4.69%+29.98%+145.16% 27.29B
Weighted average by Cap. -0.86%-3.31%+33.80%+133.54%

Financials

2026 *2027 *
Net sales 10.98M 9.46M 8.95M 8.12M 15.23M 1.05B 15.3M 106M 40.9M 533M 41.22M 40.32M 1.69B 26.17M 22.55M 21.35M 19.35M 36.3M 2.5B 36.49M 254M 97.5M 1.27B 98.27M 96.12M 4.02B
Net income -96.86M -83.45M -79.02M -71.62M -134M -9.25B -135M -938M -361M -4.71B -364M -356M -14.88B -98.04M -84.47M -79.98M -72.49M -136M -9.37B -137M -950M -365M -4.76B -368M -360M -15.06B
Net Debt -227M -196M -186M -168M -316M -21.73B -317M -2.2B -848M -11.06B -854M -836M -34.94B -297M -256M -242M -219M -412M -28.35B -414M -2.88B -1.11B -14.42B -1.11B -1.09B -45.58B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
11/09/26 USD 2.140 0.00% 4,699,044
10/09/26 USD 2.140 -5.73% 3,781,817
09/09/26 USD 2.270 -8.10% 505,801
08/09/26 USD 2.470 +0.41% 916,854
04/09/26 USD 2.460 -1.99% 496,601
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.140USD
Average target price
3.100USD
Spread / Average Target
+44.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!